Answers are grounded in this paper and cite their sources.
Background Anti-CD47 antibody therapy has demonstrated clinical activity in patients with diffuse large B-cell lymphoma (DLBCL); however, objective response rates reported in recent clinical studies range from 33% to 52%, indicating interpatient heterogeneity in therapeutic efficacy. Extracellular vesicles (EVs) can modulate immune cell function and contribute to tumor immune evasion. This study aims to elucidate EV-mediated immune evasion in DLBCL and explore an EV-based strategy to restore antitumor immune responses. Methods EVs were isolated from DLBCL patient plasma and assessed for CD47 expression. The effects of DLBCL-derived EVs (DLBCL-EVs) on macrophage-mediated phagocytosis were evaluated. The role of EV-associated CD47 in EV–macrophage interactions was assessed through antibody-mediated blockade or genetic depletion. Effects of CD47-positive lymphoma EVs and CD47 blockade were examined in an immunocompetent murine lymphoma model. M1 macrophage–derived EVs were isolated, and SIRPα expression was assessed. M1 macrophages were genetically engineered to express anti-CD19 for tumor targeting, and the derived EVs were evaluated for their ability to restore macrophage-mediated phagocytosis in vitro and for their tumor-targeting and antitumor activities in vivo. Results A substantial proportion of circulating CD47 was associated with plasma-derived EVs, with CD47 levels reduced following EV depletion. EV-associated CD47 was significantly higher in DLBCL patients than in healthy donors. Whole-plasma CD47 levels were also significantly increased in DLBCL, suggesting its potential as a convenient non-invasive biomarker. Functionally, DLBCL-EVs markedly suppressed macrophage-mediated phagocytosis. Mechanistically, EV-associated CD47 contributed to EV–macrophage binding and inhibited phagocytosis through engagement of macrophage SIRPα. Blockade or genetic depletion of CD47 on EVs reduced EVs–macrophage interactions and partially restored macrophage phagocytic activity. In vivo, CD47-positive lymphoma EVs promoted tumor growth in immunocompetent mice, whereas CD47 blockade attenuated this tumor-promoting effect. Macrophage-derived SIRPα-positive EVs were identified as natural antagonists of CD47-mediated immune evasion. Anti-CD19-M1-EVs enhanced macrophage phagocytosis in vitro and showed enhanced tumor accumulation and antitumor activity in vivo, whereas SIRPα depletion attenuated their therapeutic effect. Conclusions This study establishes EV-associated CD47 as a critical regulator of macrophage immune evasion in DLBCL and reveals Anti-CD19-M1-EVs as a novel strategy to restore antitumor phagocytosis, providing both diagnostic and therapeutic insights into DLBCL immunomodulation.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: